Strategies to Improve Asthma and Treatment of Asthma in Canadians

March 29, 2016 updated by: Ottawa Hospital Research Institute

Strategies to Improve Diagnosis and Treatment of Asthma in Canadians

Our study will enroll 644 randomly-selected Canadians who have been diagnosed with asthma by a physician within the previous five years. It will be determined what diagnostic tests were initially performed to make this diagnosis. Participants will undergo lung function testing over 6-8 weeks to determine their respiratory status and to confirm they have asthma. Participants may be followed up to one year depending on their test results.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

701

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Ottawa Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Canadians diagnosed with Asthma and 18 years of age and older.

Description

Inclusion Criteria:

  1. Patient must have a recent diagnosis of asthma by a physician. Diagnosis of asthma must have occurred within 5 years prior to entry into the study.
  2. Patient must be at least 18 years old.

Exclusion Criteria:

  1. Patients in whom methacholine challenge is contraindicated

    • Patients using chronic oral prednisone.
    • Patients with heart attack or stroke within three previous months, and those with known aortic or cerebral aneurysms.
    • Pregnant patients (unknown effect of methacholine on the fetus) and breastfeeding patients (unknown whether methacholine is excreted in breast milk).
  2. Patients unable to provide informed consent.
  3. Patients not able to perform spirometry and/or methacholine challenge testing.
  4. Patients who have a greater than 10 pack-year smoking history (this will exclude patients with possible COPD).
  5. Patients who currently have active pulmonary Tuberculosis
  6. Patients who have had eye surgery in the past 3 months or who have a detached retina
  7. Patients involved in another interventional asthma study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Shawn Aaron, MD, Ottawa Hosptial Research Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2011

Primary Completion (ACTUAL)

April 1, 2015

Study Completion (ACTUAL)

March 1, 2016

Study Registration Dates

First Submitted

January 31, 2012

First Submitted That Met QC Criteria

February 1, 2012

First Posted (ESTIMATE)

February 2, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

March 31, 2016

Last Update Submitted That Met QC Criteria

March 29, 2016

Last Verified

March 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

3
Subscribe